← All trials
NCT05030974
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Nov 30, 2022
- Completion date
- Jan 31, 2023
- First posted
- Sep 1, 2021
- Last posted
- Sep 1, 2021
- Enrollment
- 460
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of GroningenLead sponsor
- University of AmsterdamCollaborator
- Erasmus University RotterdamCollaborator
- Radboud UniversityCollaborator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- University of GroningenReponsible party - principal investigator
- University of GroningenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.